Loxapine

CHEMBL831 Phase 4 Đã phê duyệt Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

327.8 g/mol

LogP

3.1

Phase

4

A first-generation antipsychotic used to treat schizophrenia and acute agitation in bipolar disorder, available in inhaled form for rapid sedation. It blocks dopamine and serotonin receptors to reduce psychotic symptoms.

Khối lượng phân tử

327,8000 g/mol

LogP

3,10

TPSA

28,10 Å²

Lipinski RO5

Đạt

Lĩnh vực điều trị

Asthma Chronic Obstructive Pulmonary Disease Migraine Schizophrenia Bipolar Disorder Stroke Obesity

Cơ chế tác dụng

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Cấu trúc 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1

InChI

InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3

Molecular Formula

C18H18ClN3O

HBD / HBA

- / 3

Liên kết có thể quay

1

Nguyên tử nặng

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A first-generation antipsychotic used to treat schizophrenia and acute agitation in bipolar disorder, available in inhaled form for rapid sedation. It blocks dopamine and serotonin receptors to reduce psychotic symptoms.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Loxapine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL831. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3964. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Bạn đang tìm kiếm thông tin thân thiện với bệnh nhân?

Loxapine trên PillFYI

Cấu trúc

Dữ liệu nhanh

Công thức: C18H18ClN3O

Liên kết ngoài

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.